Scarica l'app Stockscreener
27.49
19.15%
3.34
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
UniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029 - MSN
(QURE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $25 to $37 - 富途牛牛
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - 富途牛牛
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
uniQure Q1 Earnings Call Highlights - Yahoo Finance
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
UniQure 1Q Loss/Shr 85c >QURE - Moomoo
uniQure Releases Q1 2026 Financial Results - AlphaStreet
Uniqure NV reports results for the quarter ended March 31Earnings Summary - TradingView
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Earnings Flash (QURE) uniQure N.V. Reports Q1 Revenue $3.6M, vs. FactSet Est of $5.2M - marketscreener.com
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - The Manila Times
UniQure: Q1 Earnings Snapshot - Barchart.com
uniQure N.V. 1Q 2026: Revenue $3.56M, Net income ($53.54M), EPS ($0.85) — 10-Q Summary - TradingView
[10-Q] uniQure N.V. Quarterly Earnings Report - Stock Titan
uniQure targets UK filing for AMT-130 as FDA seeks new trial plan - Stock Titan
uniQure (NASDAQ: QURE) Q1 2026 loss widens, holds $586.6M cash runway - Stock Titan
uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment Case - Yahoo Finance
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
UniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130 - MSN
Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE - MarketBeat
uniQure advances AMT-130 toward UK marketing approval - The Globe and Mail
Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment - 富途牛牛
Chardan Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛
symbol__ Stock Quote Price and Forecast - CNN
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - Moomoo
uniQure stock rises after regulatory updates (QURE:NASDAQ) - Seeking Alpha
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy - BioPharma Dive
uniQure (NASDAQ:QURE) Shares Gap UpHere's Why - MarketBeat
uniQure plans UK filing for Huntington’s gene therapy AMT-130 By Investing.com - Investing.com India
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure meets with UK MHRA on AMT-130 for Huntington’s disease - The Pharma Letter
Aberdeen Group (QURE) reports 5.31M shares, 8.49% stake | Schedule 13G/A - Stock Titan
uniQure plans UK filing for Huntington’s gene therapy AMT-130 - Investing.com
uniQure NV | 8-K: Current report - Moomoo
uniQure to file UK MAA for AMT-130 in Q3 2026 after positive MHRA pre-submission meeting - TradingView
AMT-130 Huntington’s gene therapy nears UK filing for uniQure (NASDAQ: QURE) - Stock Titan
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease - ChartMill
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 05 - 富途牛牛
QURE stock crashes 32% in a week: Here's what you should know - MSN
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
0.88%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):